Table 2.
Baseline Characteristics Stratified by Predicted Lifetime Risk
| Low Short‐Term/Low Lifetime Risk | Low Short‐Term/High Lifetime Risk | P Value | |
|---|---|---|---|
| N | 365 | 389 | NA |
| Age, y* | 40.5 (±7.7) | 43.1 (±8.3) | <0.001 |
| Women | 68.0% | 67.4% | 0.862 |
| Race | 0.061 | ||
| Black | 37.8% | 44.2% | |
| White | 39.7% | 40.6% | |
| Hispanic | 19.5% | 13.4% | |
| Other | 3.0% | 1.8% | |
| Smoking | 0% | 39.1% | <0.001 |
| SBP, mm Hg * | 116 (108 to 124) | 124 (113 to 136) | <0.001 |
| TC, mg/dL* | 163 (145 to 179) | 193 (161 to 214) | <0.001 |
| LDL, mg/dL* | 92 (75 to 109) | 113 (87 to 136) | <0.001 |
| HDL, mg/dL* | 50 (42 to 61) | 51 (43 to 61) | 0.260 |
| Triglycerides, mg/dL* | 76 (57 to 107) | 96 (66 to 146) | <0.001 |
| Fasting glucose, mg/dL* | 89 (82 to 95) | 90 (83 to 97) | 0.036 |
| Statin therapy | 0% | 5.7% | <0.001 |
| Antihypertensive therapy | 0% | 16.2% | <0.001 |
| BMI, kg/m2* | 26.4 (23.4 to 29.4) | 27.6 (24.1 to 31.3) | <0.001 |
| FHMI | 23.6% | 31.1% | 0.020 |
| Framingham risk* | <1% (<1% to 1%) | 1% (<1% to 2%) | <0.001 |
BMI indicates body mass index; FHMI, family history of myocardial infarction; HDL, high‐density lipoprotein cholesterol; LDL, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol.
*
Mean (±standard deviation).
*
Median (interquartile range).
*
Predicted 10 year risk of coronary heart disease events according to the Adult Treatment Panel III/Framingham risk score, median (interquartile range).